Presently there are numerous costly alternatives to Alphamir™ for treatment of HIV/AIDS in Africa. Estimates to treat the current 20 million plus infected people range from approximately $316 to $3,325 per year using presently available Highly Active Antiretroviral Treatment (HAART). In addition, the cost of the medical infrastructure for distribution, monitoring and training necessary for use of these treatment programs is prohibitive throughout Africa. Our data suggests that Alphamir™ is equally or more effective than current treatments. Clinical trials with Alphamir™ have shown no toxic effects and require minimal special training and monitoring. We are confident that clinical trials of Alphamir™ will demonstrate that it can be used as an effective vaginal gel to prevent transmission of HIV. This will be the only truly effective means of curbing the AIDS pandemic. No other current technology has this potential. In addition, the cost of our product is lower than the currently available treatments on the market. BioChem Solutions is also cost competitive when compared with the generic treatments known today. Alphamir™ is 1/5th the cost of the lowest offer from proprietary companies.